Detail of "104-86-9"

MSDS Download
CAS Number:
104-86-9
Name:
4-Chlorobenzylamine
Molecular Structure:
Formula:
C₇H₈ClN
Molecular Weight:
141.60
Synonyms:
Benzylamine, p-chloro- (8CI);Benzenemethanamine, 4-chloro-;(4-chlorophenyl)methanamine;(4-chlorophenyl)methylazanium;Benzylamine, p-chloro-;p-Chlorobenzylamine;p-Chlorobenzyl amine;
EINECS:
203-245-3
Density:
1.16 g/cm³
Boiling Point:
216.6 °C at 760 mmHg
Flash Point:
92.6 °C
Appearance:
clear slightly yellow liquid
Hazard Symbols:
Xi,C
Risk Codes:
36/37/38-34
Safety:
26-45-36/37/39 Details
Transport Information:
UN 2735

Supplier Location
Supplier Location
- China (Mainland)(13)
- United States(3)
- India(2)
- Canada(1)
- Germany(1)
Business Type
Business Type
- Lab/Research institutions(2)
- Manufacturers(0)
- Trading Company(15)
Certificates
Certificates
- ISO(2)
- Production License (0)

Display：

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Derivatives of 2,3,4,5,7,12-hexahydro-1H-(1,2,5)-triazepino[1,2-b]phthalazine-1,5-dio ne: Derivatives of 2,3,4,5,7,12-hexahydro-1H-(1,2,5)-triazepino[1,2-b]phthalazine-1,5-dio ne. Groszkowski, Stefan; Wesolowska, Barbara (Akademia Medyczna, Lodz, Pol.). Pol. PL 120339 B1 30 Nov 1983, 3 pp. (Polish). (Poland). CODEN: POXXA7. CLASS: IC: C07D487-04. APPLICATION: PL 79-215018 18 Apr 1979. DOCUMENT TYPE: Patent CA Section: 28 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 63 Title compds. I (R = H, alkyl; R1 = alkyl, aminoalkyl, hydroxyalkyl, aryl, aralkyl) were prepd. as central nervous system agents (no data). Thus,8. 81215-79-4 and 104-86-9 are cas registry numbers of chemicals which are used as reagents here.61 parts 2,3-bis(chloroacetyl)-1,2,3,4-tetrahydrophthalazine, 6.36 parts Na2CO3, and 300 vol. parts abs. EtOH were treated at reflux with 3.23 parts PhCH2NH2 in 50 vol. parts EtOH, and the mixt. was refluxed 15 h to give 82.9% title comd. II. .

Benzimidazole-5-sulfonamides as novel nonpeptide luteinizing hormone releasing hormone (LHRH) antagonists: Minimization of mechanism-based CYP3A4 inhibition: Benzimidazole-5-sulfonamides as novel nonpeptide luteinizing hormone releasing hormone (LHRH) antagonists: Minimization of mechanism-based CYP3A4 inhibition. Hashimoto, Kentaro; Kataoka, Mikayo; Tatsuta, Miyuki; Yasoshima, Kayo; Yamamoto, Mako; Yura, Takeshi; Yamamoto, Noriyuki; Urbahns, Klaus; Gupta, Jang Bahadur; Li, Yingfu (Research Center Kyoto, Bayer Yakuhin, Ltd., Kizu, Soraku, Kyoto 619-0216, Japan). Chemical & Pharmaceutical Bulletin, 53(10), 1314-1317 (English) 2005 Pharmaceutical Society of Japan. CODEN: CPBTAL. 872590-05-1 and 104-86-9 which are cas registry numbers are also used here. ISSN: 0009-2363. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 28 Herein we report the development of novel, potent and non-peptide LH releasing hormone (LHRH) antagonists. The optimization towards derivs. free from mechanism-based CYP3A4 inhibition is described. The identification of a main metabolite guided us towards structural modifications of the benzyl moiety, which resulted in significant improvements of the CYP3A4 profile, while maintaining potent LHRH antagonist activity. .